Scarica l'app Stockscreener
49.35
1.31%
0.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$48.71
Aprire:
$49.13
Volume 24 ore:
15.45M
Relative Volume:
0.96
Capitalizzazione di mercato:
$167.30B
Reddito:
$46.69B
Utile/perdita netta:
$15.29B
Rapporto P/E:
14.38
EPS:
3.4329
Flusso di cassa netto:
$9.25B
1 W Prestazione:
+3.61%
1M Prestazione:
-5.19%
6M Prestazione:
-28.06%
1 anno Prestazione:
-53.50%
Intervallo 1D:
$48.35
$49.70
Intervallo di 1 settimana:
$43.08
$49.70
Portata 52W:
$43.08
$112.52
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
49.35 | 216.44B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,075.47 | 988.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.92 | 500.07B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.70 | 402.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.40 | 250.29B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
104.83 | 259.69B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035 - GlobeNewswire Inc.
J.P. Morgan Reiterates a Buy Rating on Novo Nordisk (NVO) - Finviz
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy - Sahm
European Drugmakers And Banks Put ADRs In The Green - Finimize
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month - Sahm
Did Pfizer Just Say "Checkmate" to Novo Nordisk? - Finviz
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says - Sahm
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients - Sahm
Novo Nordisk (NVO) is Trending On RedditHere's Why - Finviz
Novo Nordisk's Wegovy Shows Weight Loss-Independent Liver Benefits in MASH Trial Data - Finviz
Why Novo Nordisk Stock Sank 5.6% Today - Finviz
European ADRs Stay Put As Novo Nordisk Slides - Finimize
Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025) - ts2.tech
Novo Nordisk's Blockbuster Weight-Loss Drug Flops In Alzheimer's Trial - Sahm
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? - Finviz
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates - ts2.tech
Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer's - Sahm
Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight - ts2.tech
Berenberg Lowers Novo Nordisk (NVO) Price Target to DKK 400, Maintains Buy Rating - Finviz
Down 45% Year-to-Date, Novo Nordisk Ignites a Price War - Finviz
Novo Nordisk (NVO) To Lower US Prices of its Injectable Wegovy Obesity Drug - Finviz
'10 minutes of murder': Why one family is speaking out about the online extremist network 764 - abcnews.go.com
Jim Cramer on Novo Nordisk: "You Gotta Let It Come Back a Little" - Finviz
What is Novo Nordisk ADR (NVO) Price Targets? - fostersleader.com
Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control - Sahm
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? - Finviz
Why Is Everyone Talking About Novo Nordisk Stock? - Finviz
Trump's MAGA backlash and the GOP's scramble for an Obamacare fix: Morning Rundown - NBC News
Will Novo Nordisk A s (b Shares) Adrhedged stock deliver long term returnsBond Market & Weekly Breakout Opportunity Watchlist - Fundação Cultural do Pará
Does Recent Drug Approval News Signal Opportunity in Novo Nordisk for 2025? - Sahm
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker - Sahm
Bernstein Remains Bullish on Novo Nordisk A/S (NVO) - Finviz
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India - Sahm
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Sahm
Why Novo Nordisk Stock Is Sinking This Week - Finviz
Even With Pricing and Competitive Pressure, Novo Nordisk's Portfolio Warrants a Wide Moat - Morningstar
Novo Nordisk ADR earnings missed by $0.09, revenue fell short of estimates - Investing.com Australia
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.31%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):